Medical Device News Magazine

BrainQ $40M Funding Round to Support Multicenter Pivotal Trial

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

BrainQ Funding Round

BrainQ, an Israeli stroke therapy technology startup today announced a $40 million funding round led by Hanaco Ventures, along with Dexcel Pharma, and Peregrine Ventures, bringing the total raised by the company to over $50 million, adding to support already secured from existing investors OurCrowd, Norma, Sailing Capital, IT Farm, Millhouse and Qure.

The funding will be used to support a multicenter pivotal trial for its groundbreaking technology for ischemic stroke survivors in selected US hospitals. This year, BrainQ received FDA Breakthrough Device Designation allowing the company to work closely with the FDA to expedite development plans and premarket clearance, with access to the new Medicare Coverage of Innovative Technology pathway.

BrainQ Co-Founder and CEO Yotam Drechsler said, “We’ve seen great advancements in increasing stroke survival rates, but it remains the leading cause of long-term disability. With new funding and strong research partners, we’re entering our pivotal study aimed at significantly increasing the window of opportunity for reducing disability and enhancing recovery potential.”

A leading causes of disability, strokes affect 800,000 people annually in the US alone. Following a stroke, the brain attempts to repair damaged neural pathways and develop new ones to restore function, often with limited success. This results in chronic disability for 50-70% of survivors.

BrainQ’s investigational technology aims to reduce disability and promote neurorecovery for stroke victims. Using a Brain Computer Interface-based approach, the company’s frequency-tuned low intensity electromagnetic field therapy is designed to operate based on biological insights retrieved from brainwaves using explanatory machine learning tools. These insights are aimed at imitating the natural processes of neural network synchronization and promoting recovery processes. The system is designed to allow for scalable and decentralized care via a portable, non-invasive wearable device that is cloud-connected with integrated telemedicine tools that enable remotely monitored sessions through an app.

BrainQ also announced the addition of a new board member, Stacey Pugh, Chief Commercial Officer of Butterfly Network, and until recently SVP and President of Medtronic’s Neurovascular business. Over the past decade, Stacey has led efforts to bring clinical evidence and products, including thrombectomy devices, one of the greatest advancements in stroke care, to markets around the world.

Stacey commented, “While I’ve had the privilege to be closely involved in some of the largest efforts for influencing stroke care, when it comes to long term recovery there is still much that can be done to restore patients’ health and abilities. I’ve been watching BrainQ’s development of their technology and clinical data for a while, and I believe their therapies have the potential to make a real difference for stroke sufferers and their families.”

Pasha Romanovski, Co-Founding Partner of lead investor Hanaco Ventures, added: “Stroke is a leading cause of adult disability in the US, affecting nearly one million people yearly. BrainQ is on the path toward developing therapies that target these disabilities caused by damaged neural networks to facilitate neurorecovery. We firmly believe in the company’s innovative technology and talented team, and are happy to support them on their amazing venture.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.